Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide currently in phase II development as an intravenous treatment ...
CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results